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Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients
With High Risk of Gastrointestinal Bleeding
Gregory Y. H. Lip, MD; Allison V. Keshishian, MPH; Yan Zhang, PhD; Amiee Kang, MPH; Amol D. Dhamane, MS; Xuemei Luo, PhD; Christian Klem, PharmD;
Mauricio Ferri, MD; Jenny Jiang, MS; Huseyin Yuce, PhD; Steven Deitelzweig, MD

Abstract
IMPORTANCE Many patients with nonvalvular atrial fibrillation (NVAF) are at a high risk of
gastrointestinal (GI) bleeding due to conditions including older age; stage III to V chronic kidney
disease (CKD); HAS-BLED (hypertension, kidney or liver disease, stroke history, prior bleeding,
unstable international normalized ratio, age >65, drug or alcohol use) score of 3 or greater;
corticosteroid, antiplatelet or nonsteroidal anti-inflammatory drug (NSAID) use; or GI conditions.
OBJECTIVE To compare the risk of stroke and/or systemic embolism (SE) and major bleeding (MB)
among patients with NVAF and high risk of GI bleeding who received non–vitamin K antagonist oral
anticoagulants (NOACs) vs those who received warfarin.

Key Points
Question How does the risk of stroke
and/or systemic embolism (SE) and
major bleeding among patients with
nonvalvular atrial fibrillation and high
risk of gastrointestinal bleeding
compare when prescribed non–vitamin
K antagonist oral anticoagulants
(NOACs) vs warfarin?
Findings In this cohort study of 381 054
patients, NOACs were associated with

DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study included patients with

lower risk of stroke and/or SE but

NVAF who were 75 years and older; had stage III to V CKD; had an HAS-BLED score of 3 or greater;

varying risks of major bleeding

used corticosteroids, antiplatelets, or NSAIDs; or had GI conditions. Data were collected from the

compared with warfarin.

Centers for Medicare & Medicaid Services and 4 commercial insurance databases between January 1,
2012, and September 30, 2015. Data analysis was conducted from January 2012 to September 2015.

Meaning These results may help inform
decision-making regarding OACs in this
high-risk patient population.

EXPOSURES New prescription for apixaban, dabigatran, rivaroxaban, or warfarin between January
1, 2013, and September 30, 2015 (identification period).
MAIN OUTCOMES AND MEASURES Six propensity score–matched cohorts were created to
compare between study drugs. For the primary objective, Cox models were used to estimate stroke

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

and/or SE and MB hazard ratios (HRs).
RESULTS A total of 381 054 patients (187 489 [49.2%] women) with NVAF and at least 1 high-risk GI
bleeding factor were identified (HAS-BLED score ⱖ3: 284 527 [74.7%]; aged ⱖ75 years: 252 835
[66.4%]; corticosteroid, antiplatelet, or NSAID therapy: 107 675 [28.3%]; prior GI bleeding
conditions: 74 818 [19.6%]; and stage III-V CKD: 56 892 [14.9%]). All NOACs were associated with a
lower risk of stroke and/or SE VS warfarin (apixaban: HR, 0.60; 95% CI, 0.52-0.68; dabigatran: HR,
0.75; 95% CI, 0.64-0.88; rivaroxaban: HR, 0.79; 95% CI, 0.73-0.86). Compared with warfarin,
apixaban and dabigatran were associated with a lower risk of MB (apixaban: HR, 0.59; 95% CI, 0.560.63; dabigatran: HR, 0.78; 95% CI, 0.70-0.86), while rivaroxaban was associated with a higher risk
(HR, 1.11; 95% CI, 1.05-1.16).
CONCLUSIONS AND RELEVANCE In this study of patients with NVAF and high risk of GI bleed,
NOACs were associated with lower rates of stroke and/or SE, but NOACs had varying risks of MB
compared with warfarin. These results may help inform treatment options in this patient population.
JAMA Network Open. 2021;4(8):e2120064. doi:10.1001/jamanetworkopen.2021.20064
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Introduction
Stroke prevention is the cornerstone of management in atrial fibrillation (AF), and oral anticoagulants
(OACs) are recommended to reduce the risk of stroke; however, there is an increased risk of
bleeding.1-4 Non–vitamin K antagonists OACs (NOACs) have been proven to be at least as effective in
stroke prevention compared with vitamin K antagonists in clinical trials and in real-world settings.5-8
However, the risk of major and gastrointestinal (GI) bleeding could affect the safety of patients after
treatment with NOACs.1
In clinical trials, apixaban, dabigatran, and edoxaban were associated with a lower MB risk
compared with warfarin7,8 and had varied risk of GI bleed: standard doses of dabigatran (150 mg,
twice a day) and edoxaban (60 mg, once a day) were associated with a higher risk, while apixaban
was associated with a lower risk. The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation (ROCKET AF) study showed rivaroxaban was associated with a similar risk of MB
compared with warfarin9 and a higher rate of GI bleeds. As such, the 2020 European Society of
Cardiology (ESC) guidelines indicate that apixaban or low-dose dabigatran (110 mg, twice a day; not
licensed in the US for AF) should be considered for patients with a recent bleeding event.10
Compared with warfarin, real-world studies found a decreased risk of GI bleed with apixaban, a
decreased-to-similar risk with dabigatran, and a similar-to-increased risk with rivaroxaban.3,11,12 These
previous studies assessed general populations of patients with nonvalvular AF (NVAF) and suggest
that the risk of GI bleeding can differ. A number of factors, such as older patient age; patient use of
nonsteroid anti-inflammatory drugs (NSAIDs); higher dose of NOAC medication; comorbid
conditions, such as kidney impairment, congestive heart failure, or chronic liver disease; and patient
history of GI bleeds, have been found to be associated with the risk of major GI bleeding in patients
with NVAF.3,5,12 It is important to identify patients with NVAF and high risk of GI bleeds based on
these risk factors for further analyses, as variable patient characteristics must be taken into account
to assist in choosing the appropriate OAC.3,5 This analysis of patients at high risk of GI bleeding in the
Anticoagulants for Reduction In Stroke: Observational Pooled Analysis on Health Outcomes and
Experience of Patients (ARISTOPHANES; NCT03087487)13 study aimed to provide complementary
evidence by comparing the rates of stroke and/or systemic embolism (SE) and major bleeding (MB)
among patients with NVAF and high risk of GI bleeding who were newly prescribed apixaban,
dabigatran, rivaroxaban, or warfarin.

Methods
This study was conducted among patients with NVAF and a high risk of GI bleeding who were newly
treated with apixaban, dabigatran, edoxaban, rivaroxaban, or warfarin—a subgroup analysis of the
ARISTOPHANES study.13 ARISTOPHANES was a retrospective cohort study that used data from the
Centers for Medicare & Medicaid Services (CMS) Medicare database and 4 US commercial claims
databases.14 Since this study did not involve the collection, use, or transmittal of individually
identifiable data, it was exempt from institutional review board review according to 45 CFR §46.
Both the data sets and the security of the offices where analysis was completed (and where the data
sets are kept) meet the requirements of the Health Insurance Portability and Accountability Act
of 1996.
Among patients included in the ARISTOPHANES study, patients with AF and an OAC pharmacy
claim between January 1, 2013, and September 30, 2015 (ie, the identification period), were chosen;
the first NOAC pharmacy claim during the identification period was designated as the index date for
patients with any NOAC claim, and the first warfarin prescription date was designated as the index
date for those without a NOAC claim. Patients prescribed edoxaban were not included in this study
given the insufficient sample size. Patient exclusion criteria are listed in Figure 1. Based on the
findings of previous studies, patients at high risk of GI bleed were identified as follows: (1) older age
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(ⱖ75 years)3,12; (2) impaired kidney function (chronic kidney disease [CKD], stage III, IV, or V or
end-stage kidney disease)3,14; (3) a score of 3 or greater on the HAS-BLED (hypertension, kidney or
liver disease, stroke history, prior bleeding, unstable international normalized ratio, age >65, drug or
alcohol use)3; (4) concomitant use of NSAIDs, antiplatelet agents, or corticosteroids at index3,14; and
(5) a past history of GI ulcers or bleeds.3,4

Outcome Measures
Primary effectiveness outcomes were stroke and/or SE, stratified by ischemic stroke, hemorrhagic
stroke, and SE. Primary safety outcome was MB, stratified by GI bleeding, intracranial hemorrhage
(ICH), and MB in other key sites (eTable 1 in the Supplement).15,16 The primary outcomes were
identified using inpatient claims with stroke and/or SE or MB as the principal (Medicare, MarketScan,
and Optum) or first-listed (Humana and PharMetrics) diagnosis.
Outcomes were measured for the follow-up period, defined as the time from 1 day after the
index date to the earliest of the following: 30 days after the discontinuation date, switch date, date
of death (inpatient and all-cause death for commercial data and Medicare populations, respectively),
end of continuous health plan enrollment, or study end (September 30, 2015).

Statistical Analysis
To control for different patient characteristics, propensity score matching (PSM) was used to
compare NOAC vs warfarin (apixaban vs warfarin, dabigatran vs warfarin, and rivaroxaban vs
warfarin) and NOAC vs NOAC (apixaban vs dabigatran, apixaban vs rivaroxaban, and dabigatran vs
rivaroxaban). Patients were matched by type and number of risk factors for GI bleeding and then
matched 1:1 by propensity scores generated using multivariable logistic regressions for baseline
characteristics, including demographic and clinical characteristics. The complete covariate list
appears in Table 1 and Table 2. Further details on PSM methodology appear in prior publications.13

Figure 1. Patient Selection Criteria
3 537 466 Had ≥1 claim for warfarin, apixaban, dabigatran,
rivaroxaban, or edoxaban during the identification period
(January 1, 2013, to September 30, 2015)

2 493 649 Had continuous enrollment for 12 mo
before the index date and were aged ≥18 y

2 165 113 Had ≥1 AF diagnosis prior to or on the index date
1 697 652 Excluded
583 061 Had diagnosis or procedure code indicative of rheumatic mitral
valvular heart disease or valve replacement procedure during
the 12 mo prior to or on the index date or were female with
pregnancy codes during the study period
323 137 Were diagnosed with VTE during the 12 mo prior to or on
the index date or had a diagnosis of with transient AF or
cardiac surgery during the 12 mo prior to or on the index date
40 328 Had a hip/knee replacement surgery within 6 wk prior to
the index date
751 126 Were prescribed >1 OAC agents on the index date, or a claim
for any OAC during 12 mo prior to the index date or
had an ICD-10 code during the study period or had
a follow-up time of 0 d

Pooled final sample
381 054 Had ≥1 risk factors for GI bleeding: prior medication, aged ≥75 y,
HAS-BLED score ≥3, prior GI bleed/ulcer, stage III-V CKD
145 063 Warfarin cohort
89 296 Apixaban cohort
28 317 Dabigatran cohort
118 378 Rivaroxaban cohort
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thromboembolism.
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Table 1. Baseline Characteristics of Patients Prescribed NOACs vs Warfarin After Propensity Score Matching
Patients, No. (%)
Apixaban vs warfarin

Dabigatran vs warfarin

Rivaroxaban vs warfarin

Apixaban cohort
(n = 62 372)

Warfarin cohort
(n = 62 372)

Dabigatran cohort
(n = 23 003)

Warfarin cohort
(n = 23 003)

Rivaroxaban cohort
(n = 76 500)

Warfarin cohort
(n = 76 500)

Mean (SD)

79.4 (7.6)

79.4 (7.5)

77.8 (7.4)

78.4 (7.8)

78.7 (7.5)

79.1 (7.7)

<65

767 (1.2)

764 (1.2)

430 (1.9)

447 (1.9)

1273 (1.7)

1299 (1.7)

65-74

14 931 (23.9)

14 934 (23.9)

6863 (29.8)

6846 (29.8)

19 212 (25.1)

19 186 (25.1)

75-79

16 011 (25.7)

15 864 (25.4)

6526 (28.4)

5412 (23.5)

21 504 (28.1)

19 319 (25.3)

≥80

30 663 (49.2)

30 810 (49.4)

9184 (39.9)

10 298 (44.8)

34 511 (45.1)

36 696 (48.0)

Male

29 747 (47.7)

29 654 (47.5)

11 656 (50.7)

11 707 (50.9)

37 449 (49.0)

37 523 (49.0)

Female

32 625 (52.3)

32 718 (52.5)

11 347 (49.3)

11 296 (49.1)

39 051 (51.0)

38 977 (51.0)

3.2 (2.7)

3.1 (2.7)

3.0 (2.6)

2.9 (2.5)

3.1 (2.6)

3.0 (2.6)

Characteristic
Age, ya

Sexa

Baseline Comorbidities
Deyo-Charlson Comorbidity Index
score, mean (SD)a
CHA2DS2-VASc score, mean (SD)
Mean (SD)

4.3 (1.5)

4.3 (1.4)

4.2 (1.4)

4.1 (1.4)

4.2 (1.4)

4.2 (1.4)

0

82 (0.1)

74 (0.1)

46 (0.2)

52 (0.2)

155 (0.2)

150 (0.2)

1

497 (0.8)

443 (0.7)

282 (1.2)

265 (1.2)

811 (1.1)

748 (1.0)

2

4933 (7.9)

4604 (7.4)

2092 (9.1)

2002 (8.7)

6604 (8.6)

6186 (8.1)

3

13 251 (21.2)

13 484 (21.6)

5308 (23.1)

5412 (23.5)

17 083 (22.3)

17 262 (22.6)

≥4

43 609 (69.9)

43 767 (70.2)

15 275 (66.4)

15 272 (66.4)

51 847 (67.8)

52 154 (68.2)

3.3 (1.2)

HAS-BLED Scoreb
Mean (SD)

3.3 (1.2)

3.3 (1.2)

3.3 (1.2)

3.2 (1.1)

3.3 (1.2)

0

35 (0.1)

30 (0.0)

17 (0.1)

24 (0.1)

76 (0.1)

67 (0.1)

1

3091 (5.0)

3168 (5.1)

1064 (4.6)

1104 (4.8)

4221 (5.5)

4237 (5.5)

2

12 042 (19.3)

11 970 (19.2)

4898 (21.3)

4851 (21.1)

15 695 (20.5)

15 688 (20.5)

≥3

47 204 (75.7)

47 204 (75.7)

17 024 (74.0)

17 024 (74.0)

56 508 (73.9)

56 508 (73.9)

Bleeding historya

13 191 (21.1)

13 220 (21.2)

4630 (20.1)

4647 (20.2)

15 998 (20.9)

16 198 (21.2)

Congestive heart failurea

19 478 (31.2)

19 289 (30.9)

6702 (29.1)

6624 (28.8)

22 585 (29.5)

22 465 (29.4)

Diabetesa

23 153 (37.1)

22 886 (36.7)

8781 (38.2)

8530 (37.1)

28 168 (36.8)

27 762 (36.3)

Hypertensiona

55 907 (89.6)

56 205 (90.1)

20 661 (89.8)

20 736 (90.1)

68 002 (88.9)

68 226 (89.2)

Kidney diseasea

16 204 (26.0)

15 686 (25.1)

4877 (21.2)

4651 (20.2)

17 482 (22.9)

16 469 (21.5)

Liver diseasea

3171 (5.1)

3065 (4.9)

1147 (5.0)

1094 (4.8)

3934 (5.1)

3811 (5.0)

Myocardial infarctiona

6140 (9.8)

5929 (9.5)

1917 (8.3)

1909 (8.3)

6985 (9.1)

6993 (9.1)

Dyspepsia or stomach discomforta

12 318 (19.7)

12 141 (19.5)

4429 (19.3)

4291 (18.7)

14 763 (19.3)

14 778 (19.3)

Non–stroke or SE peripheral vascular
diseasea

34 697 (55.6)

34 340 (55.1)

12 439 (54.1)

12 360 (53.7)

41 320 (54.0)

41 190 (53.8)

Stroke and/or SE

8914 (14.3)

9045 (14.5)

3068 (13.3)

3066 (13.3)

10 333 (13.5)

10 683 (14.0)

Transient ischemic attacka

5223 (8.4)

5257 (8.4)

1880 (8.2)

1846 (8.0)

6198 (8.1)

6247 (8.2)

Anemia and coagulation defectsa

20 025 (32.1)

19 915 (31.9)

6794 (29.5)

6766 (29.4)

23 735 (31.0)

23 690 (31.0)

Alcohol use disordera

1234 (2.0)

1237 (2.0)

538 (2.3)

512 (2.2)

1730 (2.3)

1757 (2.3)

Peripheral artery disease

13 915 (22.3)

14 284 (22.9)

4785 (20.8)

4906 (21.3)

16 733 (21.9)

16 857 (22.0)

Coronary artery disease

30 092 (48.2)

29 255 (46.9)

10 706 (46.5)

10 505 (45.7)

35 294 (46.1)

34 976 (45.7)

ACE and/or ARB

38 840 (62.3)

38 895 (62.4)

14 410 (62.6)

14 447 (62.8)

46 944 (61.4)

46 894 (61.3)

Amiodarone

7161 (11.5)

6900 (11.1)

2512 (10.9)

2397 (10.4)

8315 (10.9)

8055 (10.5)

β blockers

38 563 (61.8)

38 655 (62.0)

13 824 (60.1)

13 944 (60.6)

46 521 (60.8)

46 607 (60.9)

a

Baseline medication usea

H2-receptor antagonists

4528 (7.3)

4320 (6.9)

1656 (7.2)

1539 (6.7)

5478 (7.2)

5433 (7.1)

Proton pump inhibitors

19 967 (32.0)

19 665 (31.5)

7104 (30.9)

6859 (29.8)

23 819 (31.1)

23 476 (30.7)

Statins

38 941 (62.4)

38 901 (62.4)

13 992 (60.8)

14 073 (61.2)

46 334 (60.6)

46 270 (60.5)

Antiplatelets

13 624 (21.8)

13 221 (21.2)

4783 (20.8)

4623 (20.1)

15 766 (20.6)

15 544 (20.3)

NSAIDs

15 039 (24.1)

15 277 (24.5)

6088 (26.5)

5998 (26.1)

18 771 (24.5)

18 960 (24.8)
(continued)
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Table 1. Baseline Characteristics of Patients Prescribed NOACs vs Warfarin After Propensity Score Matching (continued)
Patients, No. (%)
Apixaban vs warfarin

Dabigatran vs warfarin

Rivaroxaban vs warfarin

Apixaban cohort
(n = 62 372)

Warfarin cohort
(n = 62 372)

Dabigatran cohort
(n = 23 003)

Warfarin cohort
(n = 23 003)

Rivaroxaban cohort
(n = 76 500)

Warfarin cohort
(n = 76 500)

Standard dosec

43 266 (69.4)

NA

18 045 (78.4)

NA

50 134 (65.5)

NA

Lower dosed

19 106 (30.6)

NA

4958 (21.6)

NA

26 366 (34.5)

NA

Characteristic
Dose of the index prescription

Follow-up time, mean (SD), d
Mean (SD)

190.8 (170.8)

249.8 (225.0)

237.6 (234.3)

253.5 (225.9)

236.4 (221.2)

251.6 (225.4)

Median (IQR)

130 (60-262)

165 (83-349)

133 (60-336)

169 (86-356)

149 (60-342)

167 (84-352)

Age ≥75 y

46 674 (74.8)

46 674 (74.8)

15 710 (68.3)

15 710 (68.3)

56 015 (73.2)

56 015 (73.2)

HAS-BLED score ≥3

47 204 (75.7)

47 204 (75.7)

17 024 (74.0)

17 024 (74.0)

56 508 (73.9)

56 508 (73.9)

Any

14 686 (23.5)

14 686 (23.5)

5684 (24.7)

5684 (24.7)

18 303 (23.9)

18 303 (23.9)

Antiplatelets

7241 (11.6)

7519 (12.1)

2519 (11.0)

2740 (11.9)

8689 (11.4)

8990 (11.8)

NSAIDs

3966 (6.4)

3925 (6.3)

1788 (7.8)

1628 (7.1)

5115 (6.7)

5129 (6.7)

Corticosteroids

4963 (8.0)

4827 (7.7)

1994 (8.7)

1907 (8.3)

6434 (8.4)

6182 (8.1)

Any

8885 (14.2)

8885 (14.2)

3368 (14.6)

3368 (14.6)

10 821 (14.1)

10 821 (14.1)

Peptic ulcer

1009 (1.6)

1070 (1.7)

349 (1.5)

372 (1.6)

1173 (1.5)

1266 (1.7)

Prior GI bleeding

2914 (4.7)

3069 (4.9)

1098 (4.8)

1079 (4.7)

3398 (4.4)

3669 (4.8)

Helicobacter pylori

245 (0.4)

251 (0.4)

83 (0.4)

95 (0.4)

293 (0.4)

300 (0.4)

Diverticulosis

5612 (9.0)

5560 (8.9)

2162 (9.4)

2171 (9.4)

6908 (9.0)

6803 (8.9)

Angiodysplasias

166 (0.3)

171 (0.3)

60 (0.3)

65 (0.3)

177 (0.2)

193 (0.3)

GI cancer (ie, stomach, colon,
esophageal, and rectal cancer)

796 (1.3)

885 (1.4)

276 (1.2)

311 (1.4)

1013 (1.3)

1064 (1.4)

Other GI lesions

590 (0.9)

378 (0.6)

161 (0.7)

154 (0.7)

594 (0.8)

496 (0.6)

8037 (12.9)

8037 (12.9)

2209 (9.6)

2209 (9.6)

7828 (10.2)

7828 (10.2)

1

20 856 (33.4)

20 856 (33.4)

8784 (38.2)

8784 (38.2)

27 435 (35.9)

27 435 (35.9)

2

23 352 (37.4)

23 352 (37.4)

8527 (37.1)

8527 (37.1)

28 681 (37.5)

28 681 (37.5)

3

14 917 (23.9)

14 917 (23.9)

4688 (20.4)

4688 (20.4)

17 042 (22.3)

17 042 (22.3)

4

3060 (4.9)

3060 (4.9)

927 (4.0)

927 (4.0)

3158 (4.1)

3158 (4.1)

5

187 (0.3)

187 (0.3)

77 (0.3)

77 (0.3)

184 (0.2)

184 (0.2)

Risk factors for GI bleeding

Prior medications

Prior GI conditions

Stage III-V CKD
Risk factors, No.

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older, diabetes,
prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65
to 74 years, sex category; CKD, chronic kidney disease; GI, gastrointestinal; HAS-BLED,
hypertension, kidney or liver disease, stroke history, prior bleeding, unstable
international normalized ratio, age 65 years or older, drug or alcohol use; IQR,
interquartile range; NA, not applicable; NOACs, non–vitamin K antagonist oral
anticoagulants; NSAIDs, nonsteroidal anti-inflammatory drugs; SE, systemic embolism.
a

b

Because the international normalized ratio value was not available in the databases, a
modified HAS-BLED score was calculated with a range of 0 to 8.

c

Standard doses are as follows: apixaban, 5 mg; dabigatran, 150 mg; and rivaroxaban,
20 mg.

d

Lower doses are as follows: apixaban, 2.5 mg; dabigatran, 75 mg; rivaroxaban, 10 or 15
mg. A total of 4569 patients received 10 mg rivaroxaban in the
rivaroxaban-warfarin cohort.

Variables controlled for in propensity score matching.

The PSM-adjusted baseline variables were compared based on standardized differences, with a
threshold of 10%.17
The incidence rates of stroke and/or SE and MB in the matched population were calculated
using the number of events divided by total person-years at risk and multiplied by 100, with KaplanMeier curves to illustrate cumulative rates. Cox proportional hazard models with robust sandwich
estimates were also applied to the PSM population to evaluate the comparative risks.18 OAC
treatment was included as the independent variable in the Cox models because all the matched
confounders were balanced after PSM between the 2 comparative cohorts. Statistical significance
was set at P < .05, and all tests were 2-tailed. For the NOAC cohorts, standard-dose (apixaban: 5 mg,
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Table 2. Baseline Characteristics of Patients Prescribed NOACs vs NOACs After Propensity Score Matching
Patients, No. (%)
Apixaban vs dabigatran

Apixaban vs rivaroxaban

Dabigatran vs rivaroxaban

Apixaban cohort
(n = 22 282)

Dabigatran cohort
(n = 22 282)

Apixaban cohort
(n = 70 093)

Rivaroxaban cohort
(n = 70 093)

Dabigatran cohort
(n = 25 123)

Rivaroxaban cohort
(n = 25 123)

Mean (SD)

78.3 (8.1)

77.7 (7.7)

78.6 (8.1)

78.2 (7.9)

76.9 (8.2)

77.1 (8.4)

<65

624 (2.8)

621 (2.8)

2072 (3.0)

2089 (3.0)

1257 (5.0)

1284 (5.1)

65-74

6551 (29.4)

6554 (29.4)

18 670 (26.6)

18 653 (26.6)

7806 (31.1)

7779 (31.0)

75-79

5312 (23.8)

6252 (28.1)

17 215 (24.6)

18 972 (27.1)

6710 (26.7)

6338 (25.2)

≥80

9795 (44.0)

8855 (39.7)

32 136 (45.8)

30 379 (43.3)

9350 (37.2)

9722 (38.7)

Male

11 161 (50.1)

11 149 (50.0)

33 780 (48.2)

33 832 (48.3)

12 989 (51.7)

12 994 (51.7)

Female

11 121 (49.9)

11 133 (50.0)

36 313 (51.8)

36 261 (51.7)

12 134 (48.3)

12 129 (48.3)

2.8 (2.5)

2.9 (2.5)

3.0 (2.6)

3.0 (2.6)

2.9 (2.5)

2.9 (2.5)

Mean (SD)

4.1 (1.4)

4.1 (1.5)

4.2 (1.5)

4.2 (1.5)

4.0 (1.5)

4.0 (1.5)

0

65 (0.3)

78 (0.4)

255 (0.4)

222 (0.3)

165 (0.7)

159 (0.6)

1

326 (1.5)

344 (1.5)

958 (1.4)

1038 (1.5)

598 (2.4)

609 (2.4)

2

2290 (10.3)

2110 (9.5)

6517 (9.3)

6529 (9.3)

2645 (10.5)

2695 (10.7)

3

5220 (23.4)

5179 (23.2)

15 596 (22.3)

15 497 (22.1)

5921 (23.6)

5895 (23.5)

≥4

14 381 (64.5)

14 571 (65.4)

46 767 (66.7)

46 807 (66.8)

15 794 (62.9)

15 765 (62.8)

Mean (SD)

3.2 (1.1)

3.2 (1.1)

3.3 (1.2)

3.3 (1.2)

3.2 (1.2)

3.2 (1.2)

0

26 (0.1)

35 (0.2)

88 (0.1)

92 (0.1)

71 (0.3)

70 (0.3)

1

1111 (5.0)

1065 (4.8)

3495 (5.0)

3557 (5.1)

1300 (5.2)

1391 (5.5)

2

4717 (21.2)

4754 (21.3)

13 825 (19.7)

13 759 (19.6)

5448 (21.7)

5358 (21.3)

≥3

16 428 (73.7)

16 428 (73.7)

52 685 (75.2)

52 685 (75.2)

18 304 (72.9)

18 304 (72.9)

Bleeding historya

4277 (19.2)

4415 (19.8)

14 449 (20.6)

14 632 (20.9)

4994 (19.9)

4904 (19.5)

Congestive heart failurea

5957 (26.7)

6222 (27.9)

19 968 (28.5)

20 014 (28.6)

6882 (27.4)

6835 (27.2)

Diabetesa

7971 (35.8)

8199 (36.8)

24 972 (35.6)

25 304 (36.1)

9312 (37.1)

9364 (37.3)

Hypertensiona

20 097 (90.2)

19 999 (89.8)

62 854 (89.7)

62 791 (89.6)

22 484 (89.5)

22 437 (89.3)

Kidney diseasea

4272 (19.2)

4426 (19.9)

15 226 (21.7)

15 723 (22.4)

4954 (19.7)

4972 (19.8)

Liver diseasea

1057 (4.7)

1084 (4.9)

3640 (5.2)

3703 (5.3)

1248 (5.0)

1233 (4.9)

Myocardial infarctiona

1767 (7.9)

1812 (8.1)

6415 (9.2)

6544 (9.3)

2027 (8.1)

2039 (8.1)

Dyspepsia or stomach discomforta

4106 (18.4)

4341 (19.5)

14 296 (20.4)

14 313 (20.4)

4946 (19.7)

4924 (19.6)

Non–stroke and/or SE peripheral
vascular diseasea

11 896 (53.4)

12 002 (53.9)

38 507 (54.9)

38 618 (55.1)

13 327 (53.0)

13 372 (53.2)

Stroke and/or SE

2801 (12.6)

2902 (13.0)

9132 (13.0)

9121 (13.0)

3129 (12.5)

3088 (12.3)

Transient ischemic attacka

1810 (8.1)

1860 (8.3)

5762 (8.2)

5740 (8.2)

1998 (8.0)

1961 (7.8)

Anemia and coagulation defectsa

6249 (28.0)

6361 (28.5)

20 890 (29.8)

21 328 (30.4)

6985 (27.8)

6952 (27.7)

Alcohol use disordera

414 (1.9)

466 (2.1)

1270 (1.8)

1287 (1.8)

647 (2.6)

635 (2.5)

Peripheral artery disease

4567 (20.5)

4558 (20.5)

14 907 (21.3)

15 349 (21.9)

5003 (19.9)

5229 (20.8)

Coronary artery disease

10 223 (45.9)

10 354 (46.5)

33 424 (47.7)

33 206 (47.4)

11 505 (45.8)

11 349 (45.2)

ACE and/or ARB

14 165 (63.6)

14 101 (63.3)

43 893 (62.6)

43 905 (62.6)

15 851 (63.1)

15 913 (63.3)

Amiodarone

2437 (10.9)

2518 (11.3)

8097 (11.6)

8075 (11.5)

2826 (11.2)

2868 (11.4)

β blockers

13 560 (60.9)

13 601 (61.0)

43 401 (61.9)

43 327 (61.8)

15 158 (60.3)

15 119 (60.2)

Characteristic
Age, ya

Sexa

Baseline comorbidities
Deyo-Charlson Comorbidity Index
score, mean (SD)a
CHA2DS2-VASc Score, mean (SD)

HAS-BLED Scoreb

a

Baseline medication usea

H2-receptor antagonists

1431 (6.4)

1518 (6.8)

5071 (7.2)

4952 (7.1)

1737 (6.9)

1790 (7.1)

Proton pump inhibitors

6847 (30.7)

7049 (31.6)

23 013 (32.8)

23 006 (32.8)

7871 (31.3)

7822 (31.1)

Statins

13 687 (61.4)

13 708 (61.5)

43 907 (62.6)

43 768 (62.4)

15 235 (60.6)

15 199 (60.5)

Antiplatelets

4682 (21.0)

4720 (21.2)

16 166 (23.1)

15 797 (22.5)

5277 (21.0)

5217 (20.8)

NSAIDs

6140 (27.6)

6214 (27.9)

19 207 (27.4)

19 133 (27.3)

7259 (28.9)

7191 (28.6)
(continued)
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Table 2. Baseline Characteristics of Patients Prescribed NOACs vs NOACs After Propensity Score Matching (continued)
Patients, No. (%)
Apixaban vs dabigatran

Apixaban vs rivaroxaban

Dabigatran vs rivaroxaban

Apixaban cohort
(n = 22 282)

Dabigatran cohort
(n = 22 282)

Apixaban cohort
(n = 70 093)

Rivaroxaban cohort
(n = 70 093)

Dabigatran cohort
(n = 25 123)

Rivaroxaban cohort
(n = 25 123)

Standard dosec

16 404 (73.6)

17 533 (78.7)

50 383 (71.9)

46 253 (66.0)

19 995 (79.6)

17 238 (68.6)

Lower dosed

5878 (26.4)

4749 (21.3)

19 710 (28.1)

23 840 (34.0)

5128 (20.4)

7885 (31.4)

Mean (SD)

194.1 (172.6)

238.3 (234.7)

191.4 (171.6)

236.2 (221.0)

236.5 (233.5)

235.7 (220.7)

Median (IQR)

134 (60-268)

134 (60-338)

130 (60-264)

149 (60-339)

133 (60-333)

150 (60-338)

Age ≥75 y

15 107 (67.8)

15 107 (67.8)

49 351 (70.4)

49 351 (70.4)

16 060 (63.9)

16 060 (63.9)

HAS-BLED score ≥3

16 428 (73.7)

16 428 (73.7)

52 685 (75.2)

52 685 (75.2)

18 304 (72.9)

18 304 (72.9)

Any

5531 (24.8)

5531 (24.8)

17 929 (25.6)

17 929 (25.6)

6672 (26.6)

6672 (26.6)

Antiplatelets

2581 (11.6)

2518 (11.3)

8690 (12.4)

8741 (12.5)

2874 (11.4)

2972 (11.8)

NSAIDs

1649 (7.4)

1776 (8.0)

5205 (7.4)

5197 (7.4)

2219 (8.8)

2122 (8.4)

Corticosteroids

1849 (8.3)

1837 (8.2)

5908 (8.4)

5987 (8.5)

2287 (9.1)

2312 (9.2)

Any

3314 (14.9)

3314 (14.9)

11 331 (16.2)

11 331 (16.2)

4164 (16.6)

4164 (16.6)

Peptic ulcer

345 (1.5)

349 (1.6)

1211 (1.7)

1196 (1.7)

417 (1.7)

456 (1.8)

Prior GI bleeding

957 (4.3)

1045 (4.7)

3422 (4.9)

3376 (4.8)

1267 (5.0)

1152 (4.6)

Helicobacter pylori

91 (0.4)

88 (0.4)

297 (0.4)

329 (0.5)

109 (0.4)

110 (0.4)

Diverticulosis

2154 (9.7)

2150 (9.6)

7243 (10.3)

7321 (10.4)

2718 (10.8)

2707 (10.8)

Angiodysplasias

48 (0.2)

48 (0.2)

204 (0.3)

179 (0.3)

60 (0.2)

65 (0.3)

GI cancer (ie, stomach, colon,
esophageal, and rectal cancer)

265 (1.2)

258 (1.2)

958 (1.4)

1017 (1.5)

305 (1.2)

356 (1.4)

Other GI lesions

242 (1.1)

166 (0.7)

826 (1.2)

647 (0.9)

219 (0.9)

268 (1.1)

1944 (8.7)

1944 (8.7)

7282 (10.4)

7282 (10.4)

2136 (8.5)

2136 (8.5)

1

8670 (38.9)

8670 (38.9)

24 543 (35.0)

24 543 (35.0)

10 007 (39.8)

10 007 (39.8)

2

8183 (36.7)

8183 (36.7)

26 221 (37.4)

26 221 (37.4)

9152 (36.4)

9152 (36.4)

3

4487 (20.1)

4487 (20.1)

15 929 (22.7)

15 929 (22.7)

4912 (19.6)

4912 (19.6)

4

883 (4.0)

883 (4.0)

3194 (4.6)

3194 (4.6)

971 (3.9)

971 (3.9)

5

59 (0.3)

59 (0.3)

206 (0.3)

206 (0.3)

81 (0.3)

81 (0.3)

Characteristic
Dose of the index prescription

Follow-up time, mean (SD), d

Risk factors for GI bleeding

Prior medications

Prior GI conditions

Stage III-V CKD
Risk factors, No.

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years or older, diabetes,
prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65
to 74 years, sex category; CKD, chronic kidney disease; GI, gastrointestinal; HAS-BLED,
hypertension, kidney or liver disease, stroke history, prior bleeding, unstable
international normalized ratio, age 65 years or older, drug or alcohol use; IQR,
interquartile range; NOACs, non–vitamin K antagonist oral anticoagulants; NSAIDs,
nonsteroidal anti-inflammatory drugs; SE, systemic embolism.
a

b

Because the international normalized ratio value was not available in the databases, a
modified HAS-BLED score was calculated with a range of 0 to 8.

c

Standard doses are as follows: apixaban, 5 mg; dabigatran, 150 mg; and
rivaroxaban, 20mg.

d

Lower doses are as follows: apixaban, 2.5 mg; dabigatran, 75 mg; rivaroxaban, 10 or 15
mg. A total of 4114 and 1443 patients received 10mg rivaroxaban in the apixabanrivaroxaban and dabigatran-rivaroxaban cohorts, respectively.

Variables controlled for in the propensity score matching.

twice a day; dabigatran: 150 mg, twice a day; rivaroxaban: 20 mg, once a day) and lower-dose
(apixaban: 2.5 mg, twice a day; dabigatran: 75 mg, twice a day; rivaroxaban: 15 mg or 10 mg once a
day) cohorts were examined separately based on index prescription dosage. Patients in the warfarin
cohort were matched to patients in the NOAC cohorts with either dosage. The statistical methods
of the main analysis were used, wherein 1:1 PSM patients in each data set were pooled and compared.
Outcomes for each of the 5 risk factors for GI bleeding were examined separately. The statistical
methods of the main analysis were used, wherein Cox proportional hazards models were conducted.
Data analysis was performed using statistical software SAS version 9.4 (SAS Institute Inc).
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Results
After applying the selection criteria, a total of 381 054 patients with NVAF and high risk of GI bleed
were identified (representing 81.6% of the total ARISTOPHANES population of 466 991 patients),
including 89 296 (23.4%) prescribed apixaban; 28 317 (7.4%), dabigatran; 118 378 (31.1%),
rivaroxaban; and 145 063 (38.1%), warfarin (Figure 1). Among patients at high risk of GI bleeding, the
mean (SD) age for those receiving apixaban, dabigatran, rivaroxaban, and warfarin was 77.9 (8.7)
years, 76.3 (8.7) years, 76.7 (8.9) years, and 78.4 (8.4) years, respectively; 187 489 patients (49.2%)
were women. Across the cohorts, the mean CCI ranged from 3.0 to 3.6, and the mean CHA2DS2VASc (congestive heart failure, hypertension, age ⱖ75 years, diabetes, prior stroke or transient
ischemic attack or thromboembolism, vascular disease, age 65-74 years, sex category) score ranged
from 4.0 to 4.3. Additional baseline characteristics for each treatment cohort can be found in
eTable 2 in the Supplement. Among these identified high-risk patients, 284 527 (74.7%) had a
HAS-BLED score of 3 or greater; 252 835 (66.4%) were aged 75 years or older; 107 675 (28.3%) used
corticosteroid, antiplatelet, or NSAID therapy at index; 74 818 (19.6%) had a prior GI bleeding
condition; and 56 892 (14.9%) had stage III to V CKD. Most patients (355 673 [93.3%]) had 3 or fewer
risk factors concurrently during the baseline period; the largest risk factor combinations were
patients aged 75 years or older with a HAS-BLED score of 3 or greater (76 723 [20.1%]), patients aged
ⱖ75 years (61 907 [16.2%]), and patients with a HAS-BLED score ⱖ3 (46 414 [12.2%]). A full
distribution of risk factor groups is shown in eFigure 1 in the Supplement.
The unadjusted incidence rate of stroke and/or SE (including ischemic stroke, hemorrhagic
stroke, and SE) was 1.5 per 100 person-years for apixaban, 1.7 per 100 person-years for dabigatran,
1.6 per 100 person-years for rivaroxaban, and 2.3 per 100 person-years for warfarin. The unadjusted
incidence rate of MB (including GI bleeding, ICH, and other MB) was 4.1 per 100 person-years for
apixaban, 4.3 per 100 person-years for dabigatran, 6.4 per 100 person-years for rivaroxaban, and 7.0
per 100 person-years for warfarin. For patients receiving apixaban, dabigatran, and rivaroxaban,
25 165 (28.2%), 5704 (20.1%), and 37 543 (31.7%) had lower dosage regimens, respectively (eTable 2
in the Supplement).
After 1:1 PSM, a total of 62 372 apixaban-warfarin, 23 003 dabigatran-warfarin, 76 500
rivaroxaban-warfarin, 22 282 apixaban-dabigatran, 70 093 apixaban-rivaroxaban, and 25 123
dabigatran-rivaroxaban PSM pairs were evaluated. All baseline variables included in the PSM logistic
models were balanced with standardized differences of less than 10% (Table 1 and Table 2).

NOAC-Warfarin Comparisons
Apixaban (hazard ratio [HR], 0.60, 95% CI, 0.52-0.68), dabigatran (HR, 0.75; 95% CI, 0.64-0.88),
and rivaroxaban (HR, 0.79; 95% CI, 0.73-0.86) use were associated with a lower risk of stroke/SE
compared with warfarin (Figure 2). Regarding MB, apixaban (HR, 0.59; 95% CI, 0.56-0.63) and
dabigatran (HR, 0.78; 95% CI, 0.70-0.86) were associated with a lower risk compared with warfarin.
Rivaroxaban (HR, 1.11; 95% CI, 1.05-1.16) was associated with a higher risk of MB vs warfarin. Likewise,
apixaban was associated with a lower risk of GI bleeding (HR, 0.59; 95% CI, 0.54-0.64), and
rivaroxaban was associated with a higher risk (HR, 1.29; 95% CI, 1.20-1.38) vs warfarin. Dabigatran
was associated with a similar risk of GI bleeding vs warfarin (HR, 1.04; 95% CI, 0.91-1.19) (Figure 2).

NOAC-NOAC Comparisons
Patients taking apixaban had a lower risk of stroke and/or SE compared with those taking dabigatran
(HR, 0.75; 95% CI, 0.62-0.91) and rivaroxaban (HR, 0.74; 95% CI, 0.67-0.83), and patients taking
dabigatran were associated with a similar risk of stroke and/or SE compared with those taking
rivaroxaban (HR, 1.12; 95% CI, 0.95-1.33) (Figure 3). Compared with dabigatran and rivaroxaban,
apixaban was associated with a lower risk of MB (dabigatran: HR, 0.74; 95% CI, 0.62-0.88;
rivaroxaban: HR, 0.55; 95% CI, 0.52-0.58) and lower risk of GI bleeding (dabigatran: HR, 0.64; 95%
CI, 0.50-0.81; rivaroxaban: HR, 0.47; 95% CI, 0.43-0.51). Compared with rivaroxaban, dabigatran
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was associated with a lower risk of MB and GI bleeding (MB: HR, 0.73; 95% CI, 0.66-0.80; GI
bleeding: HR, 0.77; 95% CI, 0.67-0.87) (Figure 3). The Kaplan-Meier curves for cumulative incidence
of stroke and/or SE and MB in the matched populations appear in eFigure 2 and eFigure 3 in the
Supplement.

Subgroup Analyses
Results of the standard-dose and low-dose subgroup analysis were generally consistent with the
main analysis for stroke and/or SE and MB in both NOAC-warfarin comparisons and NOAC-NOAC
comparisons (eTable 3 and eTable 4 in the Supplement). There was no significant difference between
low-dose dabigatran and warfarin for stroke and/or SE or MB or between standard-dose apixaban
and dabigatran for stroke and/or SE.
When each risk factor was evaluated separately, the comparative risks of stroke and/or SE and
MB were generally consistent to the main analysis for NOAC-warfarin and NOAC-NOAC comparisons,
with a few exceptions. In patients with prior corticosteroid, antiplatelet, or NSAID use, the risk of
stroke and/or SE was similar in dabigatran compared with warfarin, and the risk of stroke and/or SE
was significantly higher in dabigatran compared with rivaroxaban. In patients with stage III to V CKD,
risk of stroke and/or SE and MB was similar in dabigatran compared with warfarin; the risk of MB was
similar in dabigatran compared with rivaroxaban. In addition, among patients with stage III to V CKD
or prior corticosteroid, antiplatelet, or NSAID use, the risk of MB was similar in patients taking
rivaroxaban compared with those taking warfarin. In patients with prior GI conditions, risk of stroke
and/or SE was similar among those taking dabigatran compared with those taking warfarin, and the
risk of MB was similar in patients receiving rivaroxaban compared with those receiving warfarin. The

Figure 2. Propensity Score–Matched Incidence Rates and Hazard Ratios of Stroke and/or Systemic Embolism (SE)
and Major Bleeding for Non–Vitamin K Antagonist Oral Anticoagulant (NOAC) vs Warfarin
No. of events (incidence
per 100 person-years)
Source

NOAC

Warfarin

Hazard ratio
(95% CI)

Favors
NOAC

Favors
Warfarin

P value

Apixaban vs warfarin
466 (1.41)

933 (2.16)

0.60 (0.52-0.68)

<.001

Ischemic

374 (1.13)

641 (1.48)

0.69 (0.61-0.78)

<.001

Hemorrhagic

84 (0.25)

256 (0.59)

0.41 (0.31-0.53)

<.001

SE

11 (0.03)

41 (0.09)

0.33 (0.17-0.63)

<.001

Major bleeding

1275 (3.88)

2559 (6.00)

0.59 (0.56-0.63)

<.001

GI bleeding

620 (1.88)

1249 (2.90)

0.59 (0.54-0.64)

<.001

ICH

184 (0.55)

431 (0.99)

0.54 (0.44-0.65)

<.001

Other bleeding

545 (1.65)

1044 (2.42)

0.62 (0.56-0.68)

<.001

Stroke/SE

Dabigatran vs warfarin
232 (1.53)

326 (2.02)

0.75 (0.64-0.88)

<.001

Ischemic

193 (1.27)

217 (1.34)

0.94 (0.78-1.12)

.47

Hemorrhagic

28 (0.18)

92 (0.56)

0.32 (0.22-0.48)

<.001

SE

11 (0.07)

18 (0.11)

0.65 (0.30-1.37)

.26

Major bleeding

657 (4.36)

890 (5.57)

0.78 (0.70-0.86)

<.001

GI bleeding

403 (2.67)

419 (2.60)

1.04 (0.91-1.19)

.53

ICH

69 (0.45)

156 (0.96)

0.47 (0.36-0.61)

<.001

Other bleeding

237 (1.56)

370 (2.30)

0.68 (0.58-0.79)

<.001

Stroke/SE

Rivaroxaban vs warfarin
809 (1.61)

1071 (2.01)

0.79 (0.73-0.86)

<.001

Ischemic

588 (1.17)

726 (1.36)

0.85 (0.77-0.94)

<.001

Hemorrhagic

185 (0.36)

303 (0.56)

0.65 (0.54-0.78)

<.001

SE

39 (0.07)

48 (0.08)

0.85 (0.56-1.27)

.42

Major bleeding

3144 (6.34)

2985 (5.66)

1.11(1.05-1.16)

<.001

GI bleeding

1766 (3.54)

1437 (2.70)

1.29 (1.20-1.38)

<.001

ICH

336 (0.66)

507 (0.94)

0.70 (0.61-0.80)

<.001

Other bleeding

1293 (2.58)

1227 (2.31)

1.11 (1.03-1.19)

.007

Stroke/SE

0

0.5

1.0

1.5

Hazard ratio (95% CI)
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hazard ratios for stroke and/or SE, MB, and GI bleeding in the risk factor cohorts appear in eFigure 4
and eFigure 5 in the Supplement.

Discussion
To our knowledge, this is the largest and one of the first real-world studies to compare NOACs with
warfarin among patients with NVAF population and high risk of GI bleed. In this subgroup analysis of
the ARISTOPHANES study, NOACs were associated with lower risk of stroke and/or SE compared
with warfarin use among patients with NVAF and high risk of GI bleeding. Compared with warfarin,
apixaban and dabigatran were associated with a lower risk of MB, and rivaroxaban was associated
with a higher risk. Apixaban was associated with a lower risk of GI bleeding and rivaroxaban a higher
risk compared with warfarin. Analyses in key subgroups, including NOAC low-dose and standarddose populations and patients with each risk factor, showed generally consistent findings.
A notably high proportion of the ARISTOPHANES study cohort was at high risk, given that 82%
of patients with NVAF had at least 1 risk factor for GI bleeding. The most common risk factors were
having a HAS-BLED score of 3 or greater (74.7%) and being aged 75 years or older (66.4%); patients
with both of these risk factors accounted for the most common combination of risk factors (20.1%
of patients). Given that most patients in the ARISTOPHANES study were found to have high risk of GI
bleeding, our findings provide additional evidence regarding treatment options for this high-risk
subgroup.
In the ARISTOTLE trial, apixaban was shown to be superior to warfarin in reducing stroke and
MB.7 Consistent findings were found in this subgroup of patients with NVAF and high risk of GI

Figure 3. Propensity Score–Matched Incidence Rates and Hazard Ratios of Stroke and/or Systemic Embolism (SE)
and Major Bleeding for Non–Vitamin K Antagonist Oral Anticoagulant (NOAC) Comparisons
No. of events (incidence
per 100 person-years)
Source

Comparator

Reference

Hazard ratio
(95% CI)

Favors
comparator

Favors
reference

P value

Apixaban vs dabigatran
159 (1.32)

234 (1.59)

0.75 (0.62-0.91)

.003

Ischemic

131 (1.09)

195 (1.32)

0.74 (0.60-0.91)

.004

Hemorrhagic

24 (0.19)

27 (0.18)

0.97 (0.59-1.62)

.92

SE

<11 (0.03)

12 (0.08)

0.39 (0.13-1.19)

.10

Major bleeding

392 (3.28)

559 (4.09)

0.74 (0.62-0.88)

<.001

GI bleeding

203 (1.69)

361 (2.46)

0.64 (0.50-0.81)

<.001

ICH

63 (0.52)

63 (0.42)

1.12 (0.81-1.53)

.50

Other bleeding

150 (1.25)

221 (1.50)

0.77 (0.63-0.95)

.01

Stroke/SE

Apixaban vs rivaroxaban
489 (1.31)

755 (1.64)

0.74 (0.67-0.83)

<.001

Ischemic

382 (1.02)

551 (1.20)

0.79 (0.70-0.89)

<.001

Hemorrhagic

91 (0.24)

163 (0.35)

0.66 (0.49-0.88)

.005

SE

18 (0.04)

45 (0.09)

0.45 (0.28-0.73)

.001

Major bleeding

1393 (3.76)

2886 (6.36)

0.55 (0.52-0.58)

<.001

GI bleeding

680 (1.83)

1629 (3.57)

0.47 (0.43-0.51)

<.001

ICH

196 (0.52)

297 (0.64)

0.79 (0.65-0.95)

.01

Other bleeding

599 (1.61)

1191 (2.60)

0.57 (0.52-0.63)

<.001

Stroke/SE

Dabigatran vs warfarin
259 (1.57)

232 (1.41)

1.12 (0.95-1.33)

.18

Ischemic

214 (1.30)

182 (1.10)

0.18 (0.99-1.41)

.06

Hemorrhagic

30 (0.18)

42 (0.25)

0.72 (0.46-1.12)

.14

SE

15 (0.09)

<11 (0.06)

1.51 (0.76-2.97)

.24

Major bleeding

684 (4.18)

941 (5.79)

0.73 (0.66-0.80)

<.001

GI bleeding

413 (2.51)

542 (3.31)

0.77 (0.67-0.87)

<.001

ICH

74 (0.44)

75 (0.45)

0.99 (0.70-1.39)

.95

Other bleeding

250 (1.51)

409 (2.49)

0.61 (0.53-0.71)

<.001

Stroke/SE

0

0.5

1.0

1.5

Hazard ratio (95% CI)
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bleeding, as apixaban was shown to be associated with a lower risk of stroke and/or SE and MB
compared with warfarin in the current analysis. However, the ARISTOTLE trial found a similar risk of
GI bleeding among patients with NVAF, whereas we found apixaban to be associated with a
significantly lower risk of GI bleeding in these patients (HR, 0.59; 95% CI, 0.54-0.64). The lower risk
of GI bleeding associated with apixaban vs warfarin was also observed in the main analysis of
ARISTOPHANES.13
Few studies have evaluated the effectiveness and safety of OACs among a large group of
patients with multiple risk factors for GI bleeding. In a post hoc analysis of ARISTOTLE, baseline
NSAIDs were not found to be associated with the risk of GI bleeding, and there was no significant
interaction between NSAID use and OAC treatment (apixaban vs warfarin) for stroke and/or SE, MB,
or GI bleeding.19 In a retrospective commercial administrative claims analysis of OAC-naive patients
with NVAF and stage III to V CKD (a risk factor for GI bleeding), apixaban was associated with a lower
risk of MB compared with warfarin.5 These results were generally consistent with the findings of our
analysis.
In the RE-LY trial,8 dabigatran was found to be noninferior to warfarin for stroke and MB. Our
analysis of patients with high risk of GI bleeding showed consistent findings. Conversely, risk of GI
bleeding was found to be significantly higher in dabigatran compared with warfarin in the RE-LY trial
cohort, while our study of patients with high risk found the risk to be similar. In a retrospective
commercial administrative claims analysis of OAC-naive patients with NVAF and stage III to V CKD,
the rate of MB associated with dabigatran was similar to warfarin.5 These results were similar to the
findings of our analysis in patients with stage III to V CKD.
Rivaroxaban was found to be noninferior to warfarin for stroke and/or SE prevention in the
ROCKET AF trial, and our analysis of the subgroup of patients with high risk of GI bleeding observed
consistent findings. In ROCKET AF, the rate of all MB was found to be similar in patients treated with
rivaroxaban compared with those treated with warfarin, while the rate of GI bleeding was higher in
the rivaroxaban cohort compared with the warfarin cohort.9 In this analysis of patients with high risk
of GI bleeding, patients treated with rivaroxaban had a higher risk of MB and GI bleeding than
patients treated with warfarin. The higher risk of GI bleeding associated with rivaroxaban vs warfarin
was also observed in the main analysis of ARISTOPHANES.13 In a recent retrospective cohort analysis
of patients with NVAF and stage IV to V CKD, the risk of stroke and/or SE and MB was comparable in
patients treated with rivaroxaban vs those with warfarin.20 Our analyses of patients with stage III to V
CKD support these results, also showing comparable risks of MB and GI bleeding in patients treated
with rivaroxaban vs warfarin.
There are a limited number of real-world studies evaluating NOACs among patients with NVAF
at risk of GI bleeds. Few studies previously mentioned examined this topic5,20; a limited number of GI
risk factors were evaluated, and each subgroup was composed of a single risk factor. This study
provides a more comprehensive analysis by considering a more complete list of GI risk factors based
on the literature and evaluating risk factors in combination and individually. The latter also
reemphasizes the need to mitigate modifiable bleeding risk factors and to use bleeding risk
assessment appropriately to optimize AF care.21

Limitations
This study has several limitations. Given the nature of retrospective observational studies, no causal
relationships can be examined. In addition, the data sets engender certain specific limitations. For
example, potential residual confounders, such as over-the-counter aspirin use, and laboratory values
(eg, serum creatinine and creatinine clearance) are unavailable, and the lack of this information may
introduce bias. Further, given that International Classification of Diseases, Ninth Revision, Clinical
Modification, Current Procedural Terminology, and the Healthcare Common Procedure Coding
System codes were used to identify diagnoses and procedures, some variables in the data sets may
lack clinical accuracy due to human data entry errors. Additionally, the lack of laboratory information
(eg, lack of international normalized ratio to determine time in therapeutic range) precluded
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evaluation of the quality of warfarin control. Nevertheless, by including patients with potentially poor
quality of warfarin treatment, this study may reflect real-world clinical practice. Additionally, because
claims were used to determine the risk factors for GI bleeding, risk factors such as stage III to V CKD
or use of antiplatelets may sometimes be misclassified due to the lack of information about the
creatinine clearance for patients with CKD and over-the-counter antiplatelets, such as aspirin.

Conclusions
In this study of patients with NVAF at high risk of GI bleed, apixaban, dabigatran, and rivaroxaban
were associated with lower risk of stroke and/or SE vs warfarin; apixaban and dabigatran were
associated with lower risk of MB vs warfarin. Additionally, apixaban was associated with a lower risk
and rivaroxaban was associated with a higher risk of GI bleeding compared with warfarin. This is one
of the first real-world studies to compare NOACs in the patients with NVAF and high risk of GI bleed;
the results may help inform decision-making regarding OACs in this high-risk patient population.
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